Silo Pharma Inc SILO
NASDAQ · Vereinigte Staaten · Gesundheitstechnologie
$1,50-0,01 (-0,66 %)
Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Silo Pharma, Inc. (NASDAQ:SILO) is one of the best psychedelic stocks on our list. SILO reported on July 7 that its wholly owned subsidiary, QwikAgents, joined the NVIDIA Developer Program to support the advancement of its artificial intelligence agent integration […]
Silo Pharma (NASDAQ:SMPL) announced that its wholly owned subsidiary, QwikAgents, has joined AMD’s AI Developer Program, giving the company access to AI development resources intended to support the expansion of its enterprise and consumer AI agent platform. Key Investor TakeawaysSilo Pharma (NASDAQ:SMPL) said QwikAgents has been accepted into the AMD AI Developer Program.
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agentsSARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned
Silo Pharma Inc. (NASDAQ:SILO) shares dropped 22% on Friday after the company announced an at-the-market private placement that could raise up to $11.
Investing.com - U.S. stock index futures edged lower on Friday as investors consolidated gains following Wall Street’s sharp relief rally, with easing crude oil prices and signs of a possible diplomatic breakthrough between Washington and Tehran helping stabilize broader market sentiment.
Key Takeaways; Cannabis Sector SNDL Reported “Particularly Challenging” First Quarter 2026 Financial and Operational Results Vireo Growth Accelerated Expansion with FLUENT Acquisition, Cementing its Florida Ambitions Aurora Cannabis Expanded Global Medical Portfolio with New International Product Launches Key Takeaways; Psychedelic Sector Silo Pharma Sees Momentum as U.S. Accelerates Psychedelic PTSD Treatments Helus Pharma Expanded Veteran […]
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.